

Special Issue

Vaccine-Induced Anti-tumor Immunity

Message from the Guest Editors

Cancer is one of the leading causes of death worldwide and represents a significant public health challenge. Currently, with the success of immune checkpoint inhibition treatment, research on tumor vaccines, which are an important component of tumor immunotherapy. In order to better understand and keep up with the latest scientific advancements and development trends in the field of tumor vaccine research, this Special Issue is focused on the recent scientific and technical progress made in this field. Based on your extensive knowledge and experience, we are pleased to invite you to contribute with original research articles and reviews about cancer vaccines. Research areas may include (but are not limited to) the following:

- The design and development and anti-tumor prophylactic and therapeutic effects of tumor vaccine.
- The mechanisms of the vaccine-induced anti-tumor immune response.
- The modulation of the tumor immune microenvironment using tumor vaccines
- Combination therapy of tumor vaccines with other therapies.
- Recent advances in novel tumor prophylactic and therapeutic vaccines.

Guest Editors

Prof. Dr. Haihong Zhang

College of Life Sciences, Jilin University, Changchun, China

Prof. Dr. Xianghui Yu

School of Life Science, Jilin University, Changchun, China

Prof. Dr. Yongge Wu

National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China

Deadline for manuscript submissions

closed (30 June 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/187656

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).